|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Abgenix Inc., of Fremont, Calif., said it would receive a milestone payment from Amgen Inc., of Thousand Oaks, Calif., triggered after the latter began a pivotal trial of AMG 162. The fully human antibody was created using Abgenix's XenoMouse technology, which Amgen licensed through an April 1999 agreement. It is one of seven antibodies derived from XenoMouse technology in clinical trials, and the first product candidate from its technology out-licensing program to move into pivotal development. Patient dosing in the trial began last week. (See BioWorld Today, Aug. 11, 2004.)
o Alteon Inc., of Parsippany, N.J., said KPMG LLP resigned as its principal ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cel-Sci Acquisition Inc., of the British Virgin Islands, ...
BIOWORLD Today;
August 23, 1999 ;
700+ words
... ... Corp.'s legal counsel. (See BioWorld Today, Aug. 20, 1999, p. 1 ... Bristol-Myers Squibb Co., of New York, as part of its license and ... 87 million in cash. (See BioWorld Today, Aug. 3, 1999, p. 1 ...
|
|